Enlivex Therapeutics prices 212M shares at $1.00 in private placement

Enlivex Therapeutics (ENLV) entered into a securities purchase agreement for a private investment in public equity for the purchase and sale of 212,000,000 ordinary shares at a price of $1.00 per share, representing a premium of 11.5% from the closing price of the stock on November 21, 2025, for expected aggregate gross proceeds of approximately $212,000,000, before deducting placement agent fees and other offering expenses. Enlivex intends to use net proceeds from the PIPE to implement the first RAIN prediction markets token treasury strategy, while continuing its focus on the Company’s core business operations. The closing of the Transaction is expected to occur on or before November 25, subject to the satisfaction of customary closing conditions. BTIG is serving as the sole placement agent and exclusive financial advisor for the Transaction.